fotemustine has been researched along with Kahler Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Corso, A; Lazzarino, M; Mangiacavalli, S; Pica, G; Varettoni, M | 1 |
| Cazzola, M; Cocito, F; Corso, A; Mangiacavalli, S; Pascutto, C; Pochintesta, L; Pompa, A | 1 |
| Ardiet, C; Berger, E; Bouafia, F; Coiffier, B; Dumontet, C; Guyotat, D; Jaubert, J; Lucas, C; Sebban, C; Tranchand, B | 1 |
2 trial(s) available for fotemustine and Kahler Disease
| Article | Year |
|---|---|
Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Nitrosourea Compounds; Organophosphorus Compounds; Peripheral Nervous System Diseases; Pyrazines; Secondary Prevention; Severity of Illness Index; Survival Analysis; Thrombocytopenia | 2013 |
Clinical and pharmacokinetic phase II study of fotemustine in refractory and relapsing multiple myeloma patients.
Topics: Aged; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Neutropenia; Nitrosourea Compounds; Organophosphorus Compounds; Outpatients; Prognosis; Recurrence; Sepsis; Thrombocytopenia | 2003 |
1 other study(ies) available for fotemustine and Kahler Disease
| Article | Year |
|---|---|
Efficacy and safety of fotemustine for the treatment of relapsed and refractory multiple myeloma patients.
Topics: Adult; Antineoplastic Agents; Female; Humans; Male; Middle Aged; Multiple Myeloma; Nitrosourea Compounds; Organophosphorus Compounds; Recurrence | 2009 |